Surmodics Inc., a provider of medical device and in vitro diagnostic technologies to the health care industry, has entered into a definitive agreement to be acquired by GTCR, a private equity firm. Faegre Drinker is providing legal counsel to Surmodics Inc. in the transaction where Surmodics Inc. shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million. The transaction is expected to close in the second half of calendar year 2024. Upon completion of the transaction, Surmodics Inc. will be a privately held company and its common stock will no longer be Nasdaq listed.
Results may vary depending on your particular facts and legal circumstances.
